

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 February 2005 (24.02.2005)

PCT

(10) International Publication Number
WO 2005/017165 A1

- (51) International Patent Classification⁷: **C12N 15/63**, 15/67, A61K 48/00
- (74) Agents: LADWIG, Glenn, P. et al.; P.O. Box 142950, Gainesville, FL 32614-2950 (US).
- (21) International Application Number: PCT/US2004/026196
- (22) International Filing Date: 11 August 2004 (11.08.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|------------|------------------------------|----|
| 60/494,184 | 11 August 2003 (11.08.2003) | US |
| 60/494,185 | 11 August 2003 (11.08.2003) | US |
| 60/513,067 | 21 October 2003 (21.10.2003) | US |
| 60/513,657 | 23 October 2003 (23.10.2003) | US |
- (71) Applicant (for all designated States except US): **UNIVERSITY OF SOUTH FLORIDA** [US/US]; 4202 East Fowler Avenue, FAO 126, Tampa, FL 33620-7900 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **PHILLIPS, Ian, M.** [US/US]; 5150 Royal Cypress Circle, Tampa, FL 33647 (US). **TANG, Yao, Liang** [CN/US]; 4892 Beach Dr. SE, Apt.C, St. Petersburg, FL 33705 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STEM CELL BEACON

(57) Abstract: A stem cell-attracting chemokine is expressed in damaged tissue using a stimulus-responsive vector system. The stimulus can be a physiological stimulus associated with cell injury, such as hypoxia or elevated glucose levels, for example. Expression of the chemokine increases the trafficking of stem cells to the damaged tissue.

WO 2005/017165 A1

DESCRIPTIONSTEM CELL BEACON

5

Cross-Reference to Related Applications

The present application claims benefit of U.S. Provisional Application Serial No. 60/513,067, filed October 21, 2003, U.S. Provisional Application Serial No. 60/494,184, filed August 11, 2003, U.S. Provisional Application Serial No. 60/513,657, filed October 23, 2003, and U.S. Provisional Application Serial No. 60/494,185, filed August 11, 2003, each of which are hereby incorporated by reference herein in their entirety, including any figures, tables, nucleic acid sequences, amino acid sequences, and drawings.

Government Support

The subject matter of this application has been supported by a research grant from the National Institutes of Health under grant number 5R37HL2733423. Accordingly, the government may have certain rights in this invention.

Background of the Invention

Several common diseases such as heart failure and type 1 diabetes are characterized by cellular degeneration in the affected organ. While a variety of drugs have been developed that treat the symptoms of such diseases, in many cases these drugs do not correct the underlying cellular degeneration causing the diseases, but rather merely ameliorate some of the symptoms of the disease. A theoretically more preferable method to treat the disease is to replace the degenerating or dead cells with healthy cells, *e.g.*, by organ transplantation. Although successful in many cases, organ transplantation remains a complex process replete with both clinical and practical problems such as risk of immune system-mediated rejection and lack of donor organs.

30

Brief Summary of the Invention

The invention relates to the fields of molecular biology, gene therapy, and medicine. More particularly, the invention relates to compositions and methods for

delivering and amplifying expression of a gene encoding a stem cell-attracting chemokine in a specific tissue.

The invention relates to methods and compositions for selectively directing stem cells to a target tissue within a subject using a system that employs one or more vectors that contain a gene switch/biosensor, a tissue-specific promoter, a gene encoding a stem cell-attracting chemokine (*e.g.*, stromal-derived factor (SDF)-1 α , stem cell factor (SCF)) and a gene amplification system. The gene switch/biosensor allows expression of the chemokine-encoding gene to be regulated by a stimulus (*e.g.*, a physiological stimulus such as one associated with cellular degeneration). Thus, expression of a stem cell-attracting chemokine can be increased in response to a particular event (*e.g.*, increase in glucose concentration, decrease in oxygen concentration and mechanical stretch in vessel wall of hypertension, *etc.*). The high local concentrations of the stem cell-attracting chemokine will then cause stem cells to be recruited into and/or retained by the target tissue at a greater than normal rate. Once in the target tissue, the stem cells can differentiate (with or without the help of other agents such as morphogenesis) into new cells to replace the damaged cells and restore organ function.

Brief Description of the Drawings

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

Figure 1 is a schematic illustration of a double plasmid model for stem cell beacon vector with a hypoxia switch. In the double plasmid model, the cardiac promoter controls an oxygen-sensitive transactivator. The transactivator produces a fusion protein which binds to the inducible promoter and activates transcription of stem cell acting chemokine, SDF-1 α in the second plasmid. The oxygen-sensitive chimeric transactivator (GAL4/ODD/p65) is expressed by the transactivator plasmid under the control of the MLC-2v promoter. It can accumulate under hypoxia and activate the inducible promoter containing the GAL4 upstream activation sequence (UAS) in the reporter plasmid.

Figure 2 is a photomicrograph showing the morphologic features of mice bone marrow Lin⁻c-kit⁺ cells after labeling with PKH26. The labeling efficiency of Lin⁻c-kit⁺ cell was approximately 100%.

Figure 3 is a Western blot analysis showing an increased amount of tissue-specific hSDF-1 α expression in the ischemic mouse heart tissue compared to hSDF-1 α in the spleen, liver, lung, kidney, and muscle at 1 week after plasmid injection.

Figures 4A and 4B are photomicrographs showing immunohistochemical localization of hSDF-1 protein in cross-section of papillary muscle level 7 days after vigilant hSDF-1 plasmid transfer. Expression of hSDF-1 could be seen in the peri-infarct zone of ischemic myocardium in vigilant hSDF-1 plasmid treated MI group (Figure 4A) with less-hSDF-1 expression in vigilant treated non-MI group (Figure 4B).

Figures 5A-5D are photomicrographs of ischemic myocardium. Figure 5B is a photomicrograph of a cross section of vigilant hSDF-1 α plasmid-treated ischemic myocardium. Ischemic cardiomyocytes in the peri-infarction zone expressed hSDF-1 α (large arrowheads). The transplanted Lin⁻c-kit⁺ stem cells (small arrowheads) are clustered proximal to the hSDF-1 α positive zone. Cytoplasm was recognized by the red fluorescence of PKH26. Figure 5D is a confocal image (100 X) of the same specimen as in Figure 5C. Ischemic cardiomyocytes express hSDF-1 α (large arrowhead). The transplanted Lin⁻c-kit⁺ stem cells (small arrowheads) surround the hSDF-1 α positive cardiomyocytes. Figure 5A is ischemic myocardium without vigilant hSDF-1 α plasmid treatment. Less hSDF-1 α was expressed in ischemic tissue and few PKH26-labeled stem cells were attracted to ischemic myocardium (Figure 5B).

Figure 6 shows the effect of myocardial ischemia on hypoxia-induced hSDF-1 protein expression in mouse heart. The mouse heart underwent ischemia for one-half hour, 24 hours, 48 hours, 72 hours and 7 days. After left ventricular ischemia, the heart was analyzed for hSDF-1/6xHis protein expression. GAPDH confirmed the integrity and equal loading of protein. The time course of vigilant SDF-1 vector expression shows the hSDF-1 protein reached a peak in 24 hours after gene treatment. At 7 days, the expression of vigilant SDF-1 was stronger than endogenous SDF-1 expression. Positive SDF control is SDF-1 plasmid that can constitutively express SDF-1.

Figures 7A-7D are photomicrographs showing that expression of hSDF-1 in ischemic myocardium mobilizes labeled Lin⁻c-Kit⁺ HSC cells (red) surrounding the cardiomyocytes's expression of hSDF-1 (green). It was observed that groups of cells were positively stained for hSDF-1, and attracted more HSC, around the site in the

vigilant hSDF-1-treated MI group (Figures 7B and 7D), while less SDF-1 expression and few mobilized HSC could be seen in the medium-treated MI group (Figure 7A and 7C).

Figures 8A and 8B are bar graphs showing the infarct zone thickness (Figure 8A) and infarct size (percentage) (Figure 8B) in the ischemic myocardium shown in Figures 7A-7D, treated with vigilant hSDF-1 (VSDF-1+MI) and medium (MI; control).

Figures 9A-9D are bar graphs showing that MSCs implantation improves left ventricular function. Both LV systolic performance (LVSP) and diastolic performance (LVDP), as assessed by maximum and minimum dP/dt, respectively, were greatest in the vigilant hSDF-1 group (maximum dP/dt 3004.6 ± 362.7 in medium control vs 4057.8 ± 821.4 in vigilant hSDF-1, $p=0.0015$ (Figure 9C); minimum dP/dt -2447.2 ± 621.9 in medium control vs -3223.0 ± 455.9 in vigilant hSDF-1, $p=0.037$) (Figure 9D), indicating that both systolic and diastolic functions were best preserved in the vigilant hSDF-1_{group} after myocardial infarction versus medium group.

15

Detailed Description of the Invention

The invention provides a system for regenerating tissue by directing stem cells to a damaged organ. The system involves delivering to a target tissue, vectors that express a stem cell-attracting chemokine in response to a stimulus that is present in injured but not healthy tissue. The occurrence of a cell-injuring event thus results in production of the stem cell-attracting chemokine at the site of injury, and consequently increased trafficking of stem cells to the injured tissue. Differentiation of the stem cells at this site results in replacement of damaged cells with healthy cells – a process that results in organ regeneration.

The below described preferred embodiments illustrate adaptations of these compositions and methods. Nonetheless, from the description of these embodiments, other aspects of the invention can be made and/or practiced based on the description provided below.

Biological Methods. Methods involving conventional molecular biology techniques are described herein. Such techniques are generally known in the art and are described in detail in methodology treatises such as *Molecular Cloning: A Laboratory Manual*, 3rd ed., vol. 1-3, ed. Sambrook *et al.*, Cold Spring Harbor Laboratory Press,

Cold Spring Harbor, N.Y., 2001; and Current Protocols in Molecular Biology, ed. Ausubel *et al.*, Greene Publishing and Wiley-Interscience, New York, 1992 (with periodic updates). Methods for chemical synthesis of nucleic acids are discussed, for example, in Beaucage and Carruthers, Tetra. Letts. 22:1859-1862, 1981, and Matteucci *et al.*, J. Am. Chem. Soc. 103:3185, 1981. Chemical synthesis of nucleic acids can be performed, for example, on commercial automated oligonucleotide synthesizers. Immunological methods (*e.g.*, preparation of antigen-specific antibodies, immunoprecipitation, and immunoblotting) are described, *e.g.*, in Current Protocols in Immunology, ed. Coligan *et al.*, John Wiley & Sons, New York, 1991; and Methods of Immunological Analysis, ed. Masseyeff *et al.*, John Wiley & Sons, New York, 1992. Conventional methods of gene transfer and gene therapy can also be adapted for use in the present invention. See, *e.g.*, Gene Therapy Methods: ed. M.I. Phillips, Vol. 436, Methods in Enzymology, Academic Press, 2002; Gene Therapy: Principles and Applications, ed. T. Blackenstein, Springer Verlag, 1999; Gene Therapy Protocols (Methods in Molecular Medicine), ed. P.D. Robbins, Humana Press, 1997; and Retrovectors for Human Gene Therapy, ed. C.P. Hodgson, Springer Verlag, 1996.

Vectors. The invention employs one or more vectors to express a stem cell-attracting chemokine in response to a stimulus that is present in injured, but not healthy, tissue. A variety of different vectors might be used depending on the particular application. A preferred system of the invention uses one or more vectors that contain a gene switch/biosensor, a tissue-specific promoter operably linked to a gene encoding a stem cell-attracting chemokine, and a gene amplification system. The gene switch/biosensor allows transgene expression to be regulated by a stimulus (*e.g.*, a physiological stimulus such as hypoxia or high glucose levels). Thus, for example, expression of the gene encoding a stem cell-attracting chemokine can be modulated in response to a particular event (*e.g.*, infarction or onset of diabetes). The tissue-specific promoter allows preferential expression of the gene encoding the stem cell-attracting chemokine in a given target tissue, thereby avoiding expression in other tissues that might be harmful to the subject. The gene amplification system allows a sufficient amount of the gene encoding a stem cell-attracting chemokine to be produced to cause a desired result (*e.g.*, recruitment of stem cells to damaged tissue).

The gene switch/biosensor portion of the system can be any suitable construct that is activated in response to a stimulus associated with cell injury. In the examples described below and in Figure, 1, the gene switch/biosensor is a transactivator plasmid that includes a cardiac-specific promoter linked to a sequence encoding an oxygen-sensitive chimeric transactivator that includes a GAL4 DNA-binding domain (DBD), an oxygen-dependent degradation domain (ODD), and a p65 activation domain (p65 AD). In response to hypoxia, the transactivator binds to the GAL4 UAS sequence in the reporter plasmid (which contains a gene encoding hSDF-1 α operably linked to a GAL4 UAS).

In addition to oxygen-sensitive constructs, a number of other gene switch/biosensors are contemplated for use in the invention. Such gene switch/biosensors include a glucose switch based on the Krebs cycle (e.g., glucose response element or other glucose regulated elements), a mechanical stretch switch based on an epithelial sodium channel (ENaC), and a hypoxia response element (HRE).

The gene switch/biosensor portion of the system may include tissue-specific regulatory elements to direct tissue-specific expression of a stem cell-attracting chemokine gene. For example, to express genes specifically in the heart, a number of cardiac-specific regulatory elements can be used. An example of a cardiac-specific promoter is the ventricular form of MLC-2v promoter (see, Zhu *et al.*, *Mol. Cell Biol.* 13:4432-4444, 1993; Navankasattusas *et al.*, *Mol. Cell Biol.* 12:1469-1479, 1992) or a variant thereof such as a 281 bp fragment of the native MLC-2v promoter (nucleotides -264 to +17, Genebank Accession No. U26708). Examples of other cardiac-specific promoters include alpha myosin heavy chain (Minamino *et al.*, *Circ. Res.* 88:587-592, 2001) and myosin light chain-2 (Franz *et al.*, *Circ. Res.* 73:629-638, 1993).

In other applications, promoters that confer gene expression specific to tissues other than the heart may be used. Promoters that are kidney-specific include CLCN5 (Tanaka *et al.*, *Genomics* 58:281-292, 1999), renin (Sinn *et al.*, *Physical Genomics* 3:25-31, 2000), androgen-regulated protein, sodium-phosphate cotransporter, renal cytochrome P-450, parathyroid hormone receptor and kidney-specific cadherin. See *Am. J. Physiol. Renal Physiol.* 279:F383-392, 2000. The E-cadherin promoter directs expression specific to epithelial cells (Behrens *et al.*, *PNAS* 88:11495-11499, 1991) while the Estrogen receptor (ER) 3 gene promoter directs expression specifically to the breast epithelium

(Hopp *et al.*, *J. Mammary Gland Biol. Neoplasia* 3:73-83, 1998). Endothelial cell gene promoters include endoglin and ICAM-2. See Velasco *et al.*, *Gene Ther.* 8:897-904, 2001. Liver-specific promoters include the human phenylalanine hydroxylase (PAH) gene promoters (Bristeau *et al.*, *Gene* 274:283-291, 2001), hB1F (Zhang *et al.*, *Gene* 5 273:239-249, 2001), and the human C-reactive protein (CRP) gene promoter (Ruther *et al.*, *Oncogene* 8:87-93, 1993). An example of a muscle-specific gene promoter is human enolase (ENO3). Peshavaria *et al.*, *Biochem. J.* 292(Pt 3):701-704, 1993. A number of brain-specific promoters may be useful in the invention and include the thy-1 antigen and gamma-enolase promoters (Vibert *et al.*, *Eur. J. Biochem.* 181:33-39, 1989), the glial-specific glial fibrillary acidic protein (GFAP) gene promoter (Cortez *et al.*, *J. Neurosci. Res.* 59:39-46, 2000), and the human FGF1 gene promoter (Chiu *et al.*, *Oncogene* 19:6229-6239, 2000). The GATA family of transcription factors have promoters directing neuronal and thymocyte-specific expression. See Asnagli *et al.*, *J. Immunol.* 168:4268-4271, 2002. An example of a pancreas-specific promoter is the pancreas duodenum homeobox 1 (PDX-1) promoter. Samara *et al.*, *Mol. Cell Biol.* 22:4702-4713, 15 2002.

The vectors of the invention include a gene encoding a stem-cell attracting chemokine. Any such chemokine-encoding gene may be used in the invention. For example, genes such as SCF, vascular endothelial growth factor (VEGF), granulocyte colony-stimulating factor (G-CSF), and integrins may be used. For the applications 20 described in the Examples section, a preferred gene encoding a stem-cell attracting chemokine is one that encodes SDF-1 α , an alpha-chemokine for hematopoietic stem cells and endothelial progenitor cells. The sequences of a number of different native mammalian SDF-1 α proteins are known, including human, rat, mouse, and cat. See, *e.g.*, Shirozu *et al.*, *Genomics*, 28:495, 1995; Tashiro *et al.*, *Science* 261:600, 1993; Nishimura *et al.*, *Eur. J. Immunogenet.* 25:303, 1998; and GenBank Accession No. AF189724. 25

The vector(s) of the invention features a gene amplification system that provides a high level of tissue-specific chemokine gene expression (tissue-specific promoters typically do not allow high levels of gene expression compared to non-tissue specific promoters such as the CMV promoter). In the examples described herein, gene 30 amplification is achieved using a dual plasmid system, wherein, in response to a signal, a transactivator plasmid is induced to express a transactivator complex that binds a

regulatory element on a reporter plasmid to cause a high level of expression of the chemokine gene.

The vector(s) of the invention may also include other regulatory sequences including insulators, silencers, enhancers, initiation sites, internal ribosome entry site elements, termination signals and polyA tails. An example of a cardiac-specific enhancer is alpha BE-4. Gopal -Srivastava *et al.*, 15:7081-7090, 1995.

Vector Delivery. The vector(s) of the invention may be delivered to target tissues in any suitable manner. Several methods are known. For example, as described in the Examples section below, plasmid vectors may simply be injected into a target tissue.

Other methods for physically introducing plasmids might also be used, *e.g.*, the particle bombardment method (see Yang *et al.*, *Mol. Med. Today* 2:476-481 1996 and Davidson *et al.*, *Rev. Wound Repair Regen.* 6:452-459, 2000), electroporation (see, Preat, V., *Ann. Pharm. Fr.* 59:239-244 2001), and cationic lipid-based methods (see, Felgner *et al.*, *Ann. N.Y. Acad. Sci.* 772:126-139, 1995 and Lasic and Templeton, *Adv. Drug Delivery Rev.* 20:221-266, 1996).

In various embodiments of the invention, the nucleic acid constructs of the invention are introduced into viral vectors. Viral vector methods and protocols are reviewed in Kay *et al.* *Nature Medicine* 7:33-40, 2001. Preferred viral vectors for use in the invention are recombinant adeno-associated virus (AAV) vectors. See, *e.g.*, Tal, J., J. *Biomed. Sci.* 7:279-291, 2000 and Monahan and Samulski, *Gene Therapy* 7:24-30, 2000. In addition to AAV, other viruses may be used to create vectors useful in the invention. A list of such viruses include adenovirus (see, W.C. Russell, *Journal of General Virology* 81:2573-2604, 2000, and Bramson *et al.*, *Curr. Opin. Biotechnol.* 6:590-595, 1995), herpes simplex virus (see, Cotter and Robertson, *Curr. Opin. Mol. Ther.* 1:633-644, 1999), lentiviruses (see, Vigna and Naldini, *J. Gene Med.* 5:308-316, 2000 and Miyoshi *et al.*, *J. Virol.* 72:8150-8157, 1998), retroviruses (see Hu and Pathak, *Pharmacol. Rev.* 52:493-511, 2000 and Fong *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 17:1-60, 2000), and others (*e.g.*, alphaviruses such as Semliki Forest Virus and Sindbis Virus).

The presence of exogenous nucleic acid constructs in cells in a target tissue can be monitored by conventional methods. For example, vector-transduced cells can be assessed by PCR, flow cytometry and immunochemistry.

Target Cells (Tissues) for Introduction of Vectors *in vitro* (*ex vivo*) or *in vivo*.

Cells genetically modified with the vectors of the invention can range in plasticity from totipotent or pluripotent stem cells (*e.g.*, adult or embryonic), precursor or progenitor cells, to highly specialized cells, such as those of the central nervous system (*e.g.*, neurons and glia), pancreas, heart, lung, and liver. Stem cells can be obtained from a variety of sources, including embryonic tissue, fetal tissue, adult tissue, umbilical cord blood, peripheral blood, bone marrow, and brain, for example. Methods and markers commonly used to identify stem cells and to characterize differentiated cell types are described in the scientific literature (*e.g.*, Stem Cells: Scientific Progress and Future Research Directions, Appendix E1-E5, report prepared by the National Institutes of Health, June, 2001). The list of adult tissues reported to contain stem cells is growing and includes bone marrow, peripheral blood, umbilical cord blood, brain, spinal cord, dental pulp, blood vessels, skeletal muscle, epithelia of the skin and digestive system, cornea, retina, liver, and pancreas.

There are over 200 cell types in the human body, and the vectors of the subject invention can be introduced into any of them. A non-exhaustive list of cell types within into which vectors containing a nucleic acid sequence encoding a stem cell-attracting chemokine may be introduced is shown in Table 1. Other examples of cell types that can be genetically modified with the vectors of the invention include those disclosed by Spier R.E. *et al.*, eds., (2000) *The Encyclopedia of Cell Technology*, John Wiley & Sons, Inc., and Alberts B. *et al.*, eds., (1994) *Molecular Biology of the Cell*, 3rd ed., Garland Publishing, Inc., *e.g.*, pages 1188-1189.

Table 1. Examples of Target Cells	
Keratinizing Epithelial Cells	
keratinocyte of epidermis	
basal cell of epidermis	
keratinocyte of fingernails and toenails	
basal cell of nail bed	
hair shaft cells	
medullary	
cortical	
cuticular	
hair-root sheath cells	
cuticular	
of Huxley's layer	

Table 1. Examples of Target Cells	
of Henle's layer	external
hair matrix cell	
Cells of Wet Stratified Barrier Epithelia	
surface epithelial cell of stratified squamous epithelium of cornea tongue, oral cavity, esophagus, anal canal, distal urethra, vagina	
basal cell of these epithelia	
cell of urinary epithelium	
Epithelial Cells Specialized for Exocrine Secretion	
cells of salivary gland	
mucous cell	
serous cell	
cell of von Ebner's gland in tongue	
cell of mammary gland, secreting milk	
cell of lacrimal gland, secreting tears	
cell of ceruminous gland of ear, secreting wax	
cell of eccrine sweat gland, secreting glycoproteins	
cell of eccrine sweat gland, secreting small molecules	
cell of apocrine sweat gland	
cell of gland of Moll in eyelid	
cell of sebaceous gland, secreting lipid-rich sebum	
cell of Bowman's gland in nose	
cell of Brunner's gland in duodenum, secreting alkaline solution of mucus and enzymes	
cell of seminal vesicle, secreting components of seminal fluid, including fructose	
cell of prostate gland, secreting other components of seminal fluid	
cell of bulbourethral gland, secreting mucus	
cell of Bartholin's gland, secreting vaginal lubricant	
cell of gland of Littre, secreting mucus	
cell of endometrium of uterus, secreting mainly carbohydrates	
isolated goblet cell of respiratory and digestive tracts, secreting mucus	
mucous cell of lining of stomach	
zymogenic cell of gastric gland, secreting pepsinogen	
oxyntic cell of gastric gland, secreting HCl	
acinar cell of pancreas, secreting digestive enzymes and bicarbonate	
Paneth cell of small intestine, secreting lysozyme	
type II pneumocyte of lung, secreting surfactant	
Clara cell of lung	
Cells Specialized for Secretion of Hormones	
cells of anterior pituitary, secreting	
growth hormone	
follicle-stimulating hormone	
luteinizing hormone	
prolactin	
adrenocorticotrophic hormone	
thyroid-stimulating hormone	

Table 1. Examples of Target Cells
cell of intermediate pituitary, secreting melanocyte-stimulating hormone
cells of posterior pituitary, secreting oxytocin vasopressin
cells of gut and respiratory tract, secreting serotonin endorphin somatostatin gastrin secretin cholecystokinin insulin glucagons bombesin
cells of thyroid gland, secreting thyroid hormone calcitonin
cells of parathyroid gland, secreting parathyroid hormone oxyphil cell
cells of adrenal gland, secreting epinephrine norepinephrine steroid hormones mineralocorticoids glucocorticoids
cells of gonads, secreting testosterone estrogen progesterone
cells of juxtaglomerular apparatus of kidney juxtaglomerular cell macula densa cell peripolar cell mesangial cell
Epithelial Absorptive Cells in Gut, Exocrine Glands, and Urogenital Tract
brush border cell of intestine
striated duct cell of exocrine glands
gall bladder epithelial cell
brush border cell of proximal tubule of kidney
distal tubule cell of kidney
nonciliated cell of ductulus efferens
epididymal principal cell
epididymal basal cell
Cells Specialized for Metabolism and Storage
hepatocyte

Table 1. Examples of Target Cells	
fat cells (<i>e.g.</i> , adipocyte)	
white fat	
brown fat	
lipocyte of liver	
Epithelial Cells Serving Primarily a Barrier Function, Lining the Lung, Gut, Exocrine Glands, and Urogenital Tract	
type I pneumocyte	
pancreatic duct cell	
nonstriated duct cell of sweat gland, salivary gland, mammary gland, <i>etc.</i>	
parietal cell of kidney glomerulus	
podocyte of kidney glomerulus	
cell of thin segment of loop of Henle	
collecting duct cell	
duct cell of seminal vesicle, prostate gland, <i>etc.</i>	
Epithelial Cells Lining Closed Internal Body Cavities	
vascular endothelial cells of blood vessels and lymphatics (<i>e.g.</i> , microvascular cell)	
fenestrated	
continuous	
splenic	
synovial cell	
serosal cell	
squamous cell lining perilymphatic space of ear	
cells lining endolymphatic space of ear	
squamous cell	
columnar cells of endolymphatic sac	
with microvilli	
without microvilli	
“dark” cell	
vestibular membrane cell	
stria vascularis basal cell	
stria vascularis marginal cell	
cell of Claudius	
cell of Boettcher	
choroid plexus cell	
squamous cell of pia-arachnoid	
cells of ciliary epithelium of eye	
pigmented	
nonpigmented	
corneal “endothelial” cell	
Ciliated Cells with Propulsive Function	
of respiratory tract	
of oviduct and of endometrium of uterus	
of rete testis and ductulus efferens	
of central nervous system	
Cells Specialized for Secretion of Extracellular Matrix	
epithelial:	

Table 1. Examples of Target Cells	
ameloblast	
planum semilunatum cell of vestibular apparatus of ear	
interdental cell of organ of Corti	
nonepithelial:	
fibroblasts	
pericyte of blood capillary (Rouget cell)	
nucleus pulposus cell of intervertebral disc	
cementoblast/cementocyte	
odontoblast/odontocyte	
chondrocytes	
of hyaline cartilage	
of fibrocartilage	
of elastic cartilage	
osteoblast/osteocyte	
osteoprogenitor cell	
hyalocyte of vitreous body of eye	
stellate cell of perilymphatic space of ear	
Contractile Cells	
skeletal muscle cells	
red	
white	
intermediate	
muscle spindle-nuclear bag	
muscle spindle-nuclear chain	
satellite cell	
heart muscle cells	
ordinary	
nodal	
Purkinje fiber	
Cardiac valve tissue	
smooth muscle cells	
myoepithelial cells:	
of iris	
of exocrine glands	
Cells of Blood and Immune System	
red blood cell (erythrocyte)	
megakaryocyte	
macrophages	
monocyte	
connective tissue macrophage	
Langerhan's cell	
osteoclast	
dendritic cell	
microglial cell	
neutrophil	
eosinophil	

Table 1. Examples of Target Cells	
basophil	
mast cell	
plasma cell	
T lymphocyte	
helper T cell	
suppressor T cell	
killer T cell	
B lymphocyte	
IgM	
IgG	
IgA	
IgE	
killer cell	
stem cells and committed progenitors for the blood and immune system	
Sensory Transducers	
photoreceptors	
rod	
cones	
blue sensitive	
green sensitive	
red sensitive	
hearing	
inner hair cell of organ of Corti	
outer hair cell of organ of Corti	
acceleration and gravity	
type I hair cell of vestibular apparatus of ear	
type II hair cell of vestibular apparatus of ear	
taste	
type II taste bud cell	
smell	
olfactory neuron	
basal cell of olfactory epithelium	
blood pH	
carotid body cell	
type I	
type II	
touch	
Merkel cell of epidermis	
primary sensory neurons specialized for touch	
temperature	
primary sensory neurons specialized for temperature	
cold sensitive	
heat sensitive	
pain	
primary sensory neurons specialized for pain	
configurations and forces in musculoskeletal system	

Table 1. Examples of Target Cells
proprioceptive primary sensory neurons
Autonomic Neurons
cholinergic
adrenergic
peptidergic
Supporting Cells of Sense Organs and of Peripheral Neurons
supporting cells of organ of Corti
inner pillar cell
outer pillar cell
inner phalangeal cell
outer phalangeal cell
border cell
Hensen cell
supporting cell of vestibular apparatus
supporting cell of taste bud
supporting cell of olfactory epithelium
Schwann cell
satellite cell
enteric glial cell
Neurons and Glial Cells of Central Nervous System
neurons
glial cells
astrocyte
oligodendrocyte
Lens Cells
anterior lens epithelial cell
lens fiber
Pigment Cells
melanocyte
retinal pigmented epithelial cell
iris pigment epithelial cell
Germ Cells
oogonium/oocyte
spermatocyte
Spermatogonium
blast cells
fertilized ovum
Nurse Cells
ovarian follicle cell
Sertoli cell
thymus epithelial cell (<i>e.g.</i> , reticular cell)
placental cell

Administration of Compositions. *Ex vivo* delivery of cells transduced with rAAV vectors or infected with rAAV virus is provided for within the invention. Stem cell-mediated *ex vivo* gene therapy may be used to transplant stimulus-responsive vector system-transduced host stem cells back into the host heart. A suitable *ex vivo* protocol may include several steps. Adult stem cells may be harvested from the host and any suitable delivery vector may be used to transduce a stimulus-responsive rAAV vector system into the host's own stem cells. These genetically modified cells may then be transplanted back into the host. Several approaches may be used for the reintroduction of stem cells into the host, including jugular vein, tongue vein, intra-pericardial injection and intracardiac intravenous delivery (multiple epicardial puncture or endoventricular injection). Microencapsulation of cells transduced or infected with a stimulus-responsive rAAV vector system modified *ex vivo* is another technique that may be used within the invention. Autologous and allogeneic cell transplantation may be used according to the invention.

Any suitable delivery method may be used for transducing host stem cells or cardiac cells with a stimulus-responsive rAAV vector system *ex vivo*. Several suitable modes of delivery are described above and include the following: microinjection, electroporation, calcium phosphate transfection, DEAE dextran transfection, polylysine conjugates, receptor-mediated uptake systems, liposomes, lipid-mediated delivery systems, matrix-impregnated delivery, microparticle encapsulation, intra-cellular targeting ligands, virion-like particles, and viruses.

Effective Doses. The vectors described above are preferably administered to a mammal in an effective amount, that is, an amount capable of producing a desirable result in a treated subject (*e.g.*, regeneration of myocardium in an infarcted heart). Such a therapeutically effective amount can be determined empirically using experimental animals to determine a dose that results in a desired level of stem cell recruitment to a target tissue. It is expected that an appropriate dosage for intravenous administration of plasmids would be in the range of about 1 μ g to 1 mg per site. Different effective dose ranges will vary depending on the weight and bio-responses from the mammals used. These ranges are evident to one of ordinary skill in the art and are within the embodiments of the invention.

Stem Cells. In conjunction with administration of the above described vector system to a target tissue, to enhance the number of stem cells that home to a target tissue in an animal subject, stem cells can be administered to an animal subject and/or an agent that increases the number of available endogenous stem cells can be administered to the subject. Methods for producing stem cells for transplant are known. Any stem cells suitable for a particular application of the invention may be used. For instance, as described in the Examples section below, stem cells can be isolated from bone marrow according to expression of certain markers. *In vitro* culture methods can be used to expand the number of these cells. Stem cells isolated, and optionally expanded, in this manner can be administered to an animal (*e.g.*, by intravenous injection, direct delivery to the target tissue, or other suitable means) to increase the number of stem cells available to traffic to the target tissue. To avoid immune system-mediated rejection, the administered stem cells are preferably histocompatible with the host animal. The number of stems cell administered to a given animal subject will depend on the individual situation (*e.g.*, extent of tissue damage, type of tissue, size of animal, health of animal, *etc.*), but a therapeutic range is expected to be about 1×10^6 to about 1×10^{10} cells.

Because stem cells occur naturally in animals, a step of exogenously administering stem cells to an animal subject is not strictly required (*i.e.*, naturally occurring stem cells will traffic to the treated target tissue without need of an additional step). In many cases, however, the number of available naturally-occurring stem cells may be less than optimal to expedite regeneration of a target tissue. In these cases, the number of stem cells available in the peripheral blood can be increased by known methods. For example, the rate of stem cell movement from the bone marrow to the peripheral blood (*i.e.*, “stem cell mobilization”) can be increased by administering to a subject an agent that causes a stem cell to mobilize from the bone marrow. A number of such agents are known. See, *e.g.*, those described in International Application WO 00/50048; and colony stimulating factors such as G-CSF.

Stem Cell Differentiation. Studies from several species demonstrate that bone marrow-derived stem cells are stem cells for various mesenchymal tissues. The cells are therefore not simply stromal precursors, but precursors of peripheral tissues, such as heart muscle (Pittenger MF, Marshak DR. *Stem Cell Biology*, 949-973, 2001). Normal growth and ultimate stem cell fate depend on engraftment in an appropriate “niche”. The

mechanism by which the local milieu influences stem cell differentiation is not yet determined. Enhancement of functional activity of a specific organ's niche for heart muscle, *e.g.*, by positive inotropic (pharmacologic augment of contractility) or by positive chronotropic stimuli (heart rate increase by excise), may promote and intensify the transdifferentiation of bone marrow-derived stem cells to a cardiomyocyte phenotype. After an injury (*e.g.*, myocardial infarction), specific factors, including cytokines, stem cell factor, and various growth factors that stimulate cell replication and substitution in the injured tissue are released by surrounding cells. In addition, transplanted stem cells differentiate to cardiomyocytes and begin to express the contractile proteins specific for striated heart muscle, including Desmin, α -myosin, heavy chain, α -Actinin, and phospholamban at levels that are the same as in the host cardiomyocytes. (Strauer BE, Kornowski R *Circulation* 107:929-934, 2003).

Treatment of Various Disease States. The vector system of the invention can be adapted to a particular disease state by using an appropriate tissue-specific promoter, an appropriate stimulus-responsive element, and appropriate stem cell attracting chemokine genes for regenerating damaged tissue associated with a particular disease state. In the examples described below, this system is employed to direct homing of stem cells to ischemic cardiac tissue. The invention, however, can be directed to treat diseases other than ischemia and to target stem cells to tissues other than the heart. For example, stem cells for replacing damaged pancreatic beta cells in a type 1 diabetic patient can be induced to home to the pancreas using, in conjunction with the above-described SDF-1 α -encoding reporter vector, a transactivator vector containing a pancreas-specific promoter and a glucose sensitive element, for example, in addition to the GAL4 DBD and p65 AD sequences. Using this particular system, the transactivator vector detects elevated glucose levels in response to degenerating beta cells; it expresses a chimeric transactivator protein specifically in the pancreas. The transactivator protein then binds to the reporter vector and activates amplified expression of the gene encoding the stem cell-attracting chemokine causing stem cells to traffic to the pancreas. When glucose levels are decreased (*i.e.*, when beta cells have been replaced) the system switches off.

Thus it is clear from the invention described herein that the system is a regulated system which can be switched on or off as needed depending on the stimulus (*i.e.*, decrease/increase in glucose or decrease/increase in oxygen). The present invention

overcomes the limitation of the present state of the art by being a homeostasis sensitive system and not a constitutively “turned-on” system described in the state of the art. Moreover, the stem cells recruited into the ischemic heart or damaged liver are anti-apoptotic which is important for tissue repair to replace damaged cells, *i.e.*, are newly
5 generated myocytes or hepatocytes. These cells are natural to the host and do not become rejected or tumorigenic.

As used in this specification, including the appended claims, the singular “a”, “an”, and “the” include plural reference unless the context dictates otherwise. Thus, for example, a reference to “a polynucleotide” includes more than one such polynucleotide.
10 A reference to “a nucleic acid sequence” includes more than one such sequence. A reference to “a cell” includes more than one such cell.

The terms “comprising”, “consisting of” and “consisting essentially of” are defined according to their standard meaning. The terms may be substituted for one another throughout the instant application in order to attach the specific meaning
15 associated with each term.

The term “polypeptide” refers to any polymer comprising any number of amino acids, and is interchangeable with “protein”, “gene product”, and “peptide”.

A nucleic acid molecule can be isolated from a natural source, or it can be produced using recombinant DNA technology (*e.g.*, polymerase chain reaction (PCR)
20 amplification, cloning) or chemical synthesis. Nucleic acid molecules can be generated or modified using a variety of techniques including, but not limited to, classic mutagenesis techniques and recombinant DNA techniques, such as site-directed mutagenesis, chemical treatment of a nucleic acid molecule to induce mutations, restriction enzyme cleavage of a nucleic acid fragment, ligation of nucleic acid fragments,
25 polymerase chain reaction (PCR) amplification and/or mutagenesis of selected regions of a nucleic acid sequence, synthesis of oligonucleotide mixtures and ligation of mixture groups to “build” a mixture of nucleic acid molecules, and combinations thereof.

Although the phrase “nucleic acid molecule” (or “nucleotide molecule”) primarily refers to the physical nucleic acid molecule and the phrase “nucleic acid sequence”
30 primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably. As used herein, a “coding” nucleic acid sequence refers to a nucleic acid sequence that encodes at least a portion of a polypeptide (*e.g.*, a

portion of an open reading frame), and can more particularly refer to a nucleic acid sequence encoding a polypeptide which, when operatively linked to a transcription control sequence (*e.g.*, a promoter sequence), can express the polypeptide.

The term “operably-linked” or “operatively linked” is used herein to refer to an arrangement of flanking sequences wherein the flanking sequences so described are configured or assembled so as to perform their usual function. Thus, a flanking sequence operably-linked to a coding sequence may be capable of effecting the replication, transcription and/or translation of the coding sequence. For example, a coding sequence is operably-linked to a promoter when the promoter is capable of directing transcription of that coding sequence. A flanking sequence need not be contiguous with the coding sequence, so long as it functions correctly. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence, and the promoter sequence can still be considered “operably-linked” to the coding sequence.

As used herein, the term “isolated” means removal from its native environment, and can include removal from its immediate native environment.

As used herein, the term “differentiated” refers to those cells that maintain in culture all, or a substantial amount of, their specialized structure and function typical of the cell type *in vivo*. Partially differentiated cells maintain less than a substantial amount of their full complement of specialized structure and/or function.

Nucleic acid constructs comprising a gene switch/biosensor and a nucleic acid sequence encoding a stem cell-attracting chemokine, which is expressed in response to a stimulus that is present in injured but not health tissue, may be introduced into stem cells, progenitor cells, or mature (differentiated) cells, for example. As used herein, the term “stem cell” is an unspecialized cell that is capable of replicating or self renewal, and developing into specialized cells of a variety of cell types. The product of a stem cell undergoing division is at least one additional stem cell that has the same capabilities of the originating cell. For example, under appropriate conditions, a hematopoietic stem cell can produce a second generation stem cell and a neuron. Stem cells include embryonic stem cells (*e.g.*, those stem cells originating from the inner cells mass of the blastocyst) and adult stem cells (which can be found throughout the more mature animal, including humans). As used herein, stem cells are intended to include those stem cells found in

animals that have matured beyond the embryonic stage (*e.g.*, fetus, infant, adolescent, juvenile, adult, *etc.*). The list of tissues reported to contain stem cells is growing and includes, for example, bone marrow, peripheral blood, brain, spinal cord, umbilical cord blood, amniotic fluid, placenta, dental pulp, blood vessels, skeletal muscle, epithelia of the skin and digestive system, cornea, retina, liver, and pancreas.

As used herein, the term “progenitor cell” (also known as a precursor cell) is unspecialized or has partial characteristics of a specialized cell that is capable of undergoing cell division and yielding two specialized cells. For example, a myeloid progenitor/precursor cell can undergo cell division to yield two specialized cells (a neutrophil and a red blood cell).

As used herein, the term “phenotype” refers to all the observable characteristics of a cell (or organism); its shape (morphology); interactions with other cells and the non-cellular environment (*e.g.*, extracellular matrix); proteins that appear on the cell surface (surface markers); and the cell’s behavior (*e.g.*, secretion, contraction, synaptic transmission).

As used herein, the terms “administer”, “apply”, “treat”, “transplant”, “implant”, “deliver”, and grammatical variations thereof, are used interchangeably to provide vectors of the subject invention to target cells *in vitro* (*e.g.*, *ex vivo*) or *in vivo*, or provide genetically modified cells of the subject invention to a subject.

As used herein, the term “co-administration” and variations thereof refers to the administration of two or more agents simultaneously (in one or more preparations), or consecutively. For example, one or more types of genetically modified cells of the invention can be co-administered with other agents.

Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Commonly understood definitions of molecular biology terms can be found in Rieger *et al.*, Glossary of Genetics: Classical and Molecular, 5th edition, Springer-Verlag: New York, 1991; and Lewin, Genes V, Oxford University Press: New York, 1994. Commonly understood definitions of virology terms can be found in Granoff and Webster, Encyclopedia of Virology, 2nd edition, Academic Press: San Diego, CA, 1999; and Tidona and Darai, The Springer Index of Viruses, 1st edition, Springer-Verlag: New York, 2002. Commonly understood definitions of microbiology can be found in

Singleton and Sainsbury, Dictionary of Microbiology and Molecular Biology, 3rd edition, John Wiley & Sons: New York, 2002.

Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below.

Examples

The invention can be illustrated by the following examples in which a dual plasmid vector system is used to detect and respond to hypoxia in cardiac tissue. The first plasmid is the “transactivator” plasmid. This contains a cardiac-specific promoter linked to a sequence encoding an oxygen-sensitive chimeric transactivator that includes a GAL4 DBD, an ODD, and a p65 AD. The second plasmid is the “reporter” plasmid which contains a gene encoding hSDF-1 α (a stem cell attracting chemokine) linked to a GAL4 UAS. The “transactivator” plasmid expresses the chimeric transactivator specifically in the heart. In response to hypoxia, the transactivator binds to the GAL4 UAS sequence in the reporter plasmid, resulting in the expression of the hSDF-1 α gene. The resulting high local concentration of hSDF-1 α gene results in higher levels of homing of stem cells to the damaged tissue.

Example 1 – Construction of Plasmids

To make the transactivator plasmid, the ODD (amino acids 394-603; see Huang *et al. Proc Natl Acad Sci U S A.* 95:7987, 1998) was amplified by PCR from pCEP4/HIF-1 α (Semenza *et al. J Biol Chem.* 271:32529, 1996) and inserted in frame between the coding sequence of GAL4 DBD and p65AD in pGS-MLC to generate pGS-MLC-ODD (see Figure 1). pGS-CMV is a plasmid that expresses a chimeric transcription factor consisting of the yeast GAL4 DBD (amino acids 1-93; Keegan *et al., Science.* 231:699, 1986) and the human p65AD (amino acids 283-551; Schmitz *et al., EMBO J.* 10:3805, 1991) from NF- κ B under the control of a 281bp MLC-2v promoter.

The reporter plasmid, pGene-hSDF-1 α -6his (Figure 1), encodes stem cell-attracting chemokine SDF-1 α driven by six copies of a 17bp GAL4 UAS (Giniger *et al., Cell.* 40:767, 1985) and an adenovirus E1b TATA box (Lillie and Green, *Nature.* 338:39, 1989). It was derived from pGene/V5-His/*lacZ* (INVITROGEN, Carlsbad, CA) by

replacing the *lacZ* coding sequence with a hSDF-1 α cDNA. The identity of clones was confirmed by nucleotide sequence analysis.

Example 2 –Testing the Plasmids *In Vivo*

5 Preparation of bone marrow stem cell- Bone marrow was harvested from femur and tibia of BALB/c mice. Mononuclear cells isolated from bone marrow were sorted to separate Lin⁻ cells with Lin cocktail by SPINSEP cell enrichment procedure (Stem Cell Technologies Inc., Vancouver, Canada). The Lin⁻ bone marrow stem cells were enriched for c-kit⁺ cells using a c-kit MACS microbead system (MACS bead and apparatus from
10 Dynal Biotech, Oslo, Norway; biotin-conjugated rat anti-mouse c-kit monoclonal antibody from BD biosciences, San Jose, CA). After isolation the Lin⁻c-kit⁺ cells were resuspended in staining medium containing PKH26-GL (Sigma Company, St. Louis, MO). Referring to Figure 2, the mouse Lin⁻c-kit⁺ stem cells were relatively homogenous in appearance. The labeling efficiency with PKH26 was approximately 100%.

15 MI generation, gene therapy, and stem cell therapy - Age-matched 8-week-old BALB/c mice were used in a MI model. Mice were anesthetized, intubated and mechanically ventilated. A thoracotomy incision was made in the fourth intercostals space and the proximal left anterior descending (LAD) coronary artery was surgically occluded with an 8-0 non-absorbable suture. Successful coronary occlusion was
20 confirmed by a change of ST segment on the EKG from a limb lead. In sham mice, ligation was placed beside the coronary artery. Simultaneously, adult BALB/c mice (n=10/group) were injected intra-myocardially with two plasmids: pGS-MLC-ODD (40 μ g) and pGene-SDF-1 α -6his (20 μ g), while control mice (n=10) received saline injection only. PKH26-labeled Lin⁻c-kit⁺ stem cells were systemically injected into the
25 mice.

Western blot - Heart and other tissue samples from the mice were homogenized in Tris (12.5 mM/l) buffer (pH 6.8) containing glycerol (10%), SDS (4%), and β -mercaptoethanol (1.8%). Twenty-five μ g of soluble protein from each sample was separated by gel electrophoresis (using a 12% Ready Gel gel from BIORAD, CA, USA),
30 and Western blotting was carried out using and antibody to His (C-term) (1:1,000, INVITROGEN Inc., Carlsbad, CA). The relative amounts of hSDF-1 α protein expression were determined by densitometric analysis.

Assessment of SDF-1 α and identification of stem cells in the heart - Hearts were collected from the experimental animals 1 week after MI for detection of SDF-1 α expression and identification of stem cells that localized to ischemic heart tissue. The expression of SDF-1 α in ischemic heart tissue was detected by immunohistochemistry using an antibody to hSDF-1 α or this using DAKO EnVision Systems Alkaline Phosphatase kit (DAKO, Cambridge, MA). Confocal imaging and immunofluorescent staining was also used to identify both the expression of hSDF-1 α (using a FITC-labeled secondary antibody) and the labeled transplanted stem cells (previously labeled with PKH26).

Example 3-Results

Mice whose hearts were transfected with the MLC-ODD dual plasmid system then subjected to ischemia by ligation of LAD showed higher tissue-specific expression of hSDF-1 α in the ischemic mouse heart tissue than in the spleen, liver, lung, kidney and muscle at 1 week after intracardiac plasmid injection (see Western blot shown in Figure 3). One week after intracardiac injection of plasmid, immunohistochemical staining showed that hSDF-1 α was clearly present in ischemic myocardium (Figure 4A) of mice and absent in the control (mice that did not undergo MI; Figure 4B). Transplanted stem cells were attracted to the SDF-1 α -expressing peri-infarct zone (the ischemic tissue) in a dose-dependent manner with increasing time (Figures 5A-5D). This amplification did not compromise the cardiac specificity of MLC-2v promoter, which still maintained the previously observed expression profile (*i.e.*, higher in ischemic heart than in the non-cardiac tissues).

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.

- 5 It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application.

Claims

What is claimed is:

1. A composition comprising:
 - (a) a first polynucleotide comprising:
 - (1) a gene switch/biosensor comprising a nucleic acid sequence encoding a physiological stimulus-sensitive chimeric transactivator, and
 - (2) an operatively linked tissue-specific promoter; and
 - (b) a second polynucleotide comprising a nucleic acid sequence encoding a stem cell-attracting chemokine.
2. The composition of claim 1, wherein said physiological stimulus-sensitive chimeric transactivator is oxygen-sensitive and comprises a GAL4 DNA-binding domain (DBD), a oxygen-dependent degradation domain (ODD), and a p65 activation domain (p65 AD); and wherein said second polynucleotide further comprises a GAL4 upstream activating sequence (UAS) linked to said nucleic acid sequence of said second polynucleotide, and wherein in response to hypoxia, said transactivator binds to the GAL4 UAS, resulting in expression of said nucleic acid sequence encoding said stem cell-attracting chemokine.
3. The composition of claim 1 or 2, wherein said tissue-specific promoter is specific for expression in a tissue selected from the group consisting of kidney, epithelial tissue, endothelial tissue, liver, brain, neural tissue, thymus, and pancreas.
4. The composition of any of claims 1 to 3, wherein said tissue-specific promoter is selected from the group consisting of CLCN5, rennin, androgen-regulated protein, sodium-phosphate cotransporter, renal cytochrome P-450, parathyroid hormone receptor, kidney-specific cadherin, E-cadherein, estrogen receptor (ER) 3, endoglin, ICAM-2, human phenylalanine hydroxylase (PAH), human C-reactive protein (CRP), human enolase (ENO3), thy-1 antigen, gamma-enolase, glial-specific glial fibrillary acidic protein (GFAP), human FGF1, GATA transcription factor, and pancreas duodenum homeobox 1 (PDX-1).

5. The composition of claim 1 or 2, wherein said tissue-specific promoter is a cardiac-specific promoter.

6. The composition of any of claims 1 to 3, wherein said tissue-specific promoter is a cardiac-specific promoter selected from the group consisting of the ventricular form of the MLC-2v promoter, a fragment of the native MLC-2v promoter, alpha myosin heavy chain promoter, and myosin light chain-2 promoter.

7. The composition of any of claims 1 to 4, wherein said stem cell-attracting chemokine is selected from the group consisting of SCF, vascular endothelial growth factor (VEGF), granulocyte colony-stimulating factor (G-CSF), an integrin, and hSDF-1alpha.

8. The composition of any of claims 1 to 4, wherein said stem cell-attracting chemokine comprises hSDF-1alpha.

9. The composition of any of claims 1 to 4, wherein said physiological stimulus is associated with cell injury.

10. The composition of any of claims 1 to 4, wherein said physiological stimulus-sensitive chimeric transactivator is oxygen-sensitive (sensitive to hypoxia) or glucose-sensitive (sensitive to high glucose levels).

11. The composition of any of claims 1 to 6, wherein the stem cell attracted by said stem cell-attracting chemokine is from an anatomical site selected from the group consisting of bone marrow, peripheral blood, brain, spinal cord, dental pulp, blood vessels, skeletal muscle, epithelia of the skin, epithelia of the digestive system, cornea, retina, liver, and pancreas.

12. The composition of any of claims 1 to 10, wherein said composition is a recombinant viral vector.

13. The composition of any of claims 1 to 12, wherein said composition is a recombinant viral vector selected from the group consisting of an adenovirus, an adeno-associated virus, a herpes simplex virus, a lentivirus, and a retrovirus.

14. The composition of any of claims 1 to 12, wherein said composition is a recombinant adeno-associated viral vector.

15. The composition of any of claims 1 to 11, wherein said composition is a non-viral vector.

16. The composition of any of claims 1 to 11, wherein said composition is a plasmid.

17. A method of targeting a stem cell to a target tissue in an animal subject, the method comprising administering to the target tissue the composition of any of claims 1 to 16.

18. The method of claim 17, wherein the composition is administered to a cell by a delivery method selected from the group consisting of microinjection, electroporation, calcium phosphate transfection, DEAE dextran transfection, polylysine conjugates, receptor-mediated uptake system, liposomal delivery, lipid-mediated delivery system, matrix-impregnated delivery system, microparticle encapsulation, intra-cellular targeting ligand, virion-like particles, and viruses.

19. The method of claim 17 or 18, wherein the target tissue is selected from the group consisting of bone marrow, blood, brain, blood vessels, spinal cord, peripheral nerve, skeletal muscle, cornea, retina, lungs, liver, and pancreas.

20. The method of any of claims 17 to 19, wherein said administering comprises administering the composition to host cells *in vitro* and subsequently administering the host cells to a subject.

21. The method of any of claims 17 to 19, wherein said administering comprises administering the composition to the target tissue *in vivo*.

22. The method of any of claims 17 to 21, wherein following said administering, the nucleic acid sequence encoding the stem cell-attracting chemokine is expressed in the target tissue, and wherein the chemokine attracts endogenous stem cells or endogenous progenitor cells to the target tissue.

23. The method of any of claims 17 to 22, wherein said method further comprises co-administering stem cells to the target tissue.

24. The method of any of claims 17 to 23, wherein said method further comprises administering an agent that causes stem cells to migrate to the target tissue.

25. The method of any of claims 17 to 24, wherein the target tissue is damaged.

26. The method of any of claims 17 to 24, wherein the target tissue is at increased risk of damage.

27. A composition comprising:

(a) a first polynucleotide comprising:

- (1) a tissue-specific promoter,
- (2) a nucleic acid sequence encoding a GAL4 DNA-binding domain,
- (3) a nucleic acid sequence encoding an ODD polypeptide, and
- (4) a nucleic acid sequence encoding a p65 activation domain; and

(b) a second polynucleotide comprising:

- (1) at least two copies of a GAL4 UAS,
- (2) a TATA element, and
- (3) a nucleic acid sequence encoding a stem cell-attracting chemokine.

28. A method of targeting a stem cell to a target tissue in an animal subject, the method comprising administering to the target tissue the composition of claim 27.




FIG. 1

2/18



FIG. 2

3/18

Ischemic Heart

SDF-1 α
-6His



Muscle Liver Spleen Lung Kidney

FIG. 3

4/18




FIG. 4A

5/18



FIG. 4B

6/18




FIG. 5A



FIG. 5B

7/18





FIG. 5C



8/18




FIG. 6

9/18




FIG. 7A

10/18




FIG. 7B

11/18




FIG. 7C

12/18




FIG. 7D

13/18




FIG. 8A




FIG. 8B

15/18




FIG. 9A




FIG. 9B

17/18




FIG. 9C




FIG. 9D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/026196

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/63 C12N15/67 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, BIOSIS, MEDLINE, WPI Data, PAJ, CHEM ABS Data, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	TANG YI ET AL: "Hypoxia inducible double plasmid system for myocardial ischemia gene therapy" HYPERTENSION (BALTIMORE), vol. 39, no. 2 Part 2, February 2002 (2002-02), pages 695-698, XP002304487 ISSN: 0194-911X	1,2,5,7, 9-16,27
Y	the whole document ----- -/-	17-26,28

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

° Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 November 2004

Date of mailing of the international search report

01/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Authorized officer

P i l a t n

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2004/026196

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>PHILLIPS M IAN ET AL: "Vigilant vector: Heart-specific promoter in an adeno-associated virus vector for cardioprotection" HYPERTENSION (BALTIMORE), vol. 39, no. 2 Part 2, February 2002 (2002-02), pages 651-655, XP002304486 ISSN: 0194-911X the whole document</p>	1,2,5,7, 9-16
Y	<p>TANG YI ET AL: "Vigilant vectors: Adeno-associated virus with a biosensor to switch on amplified therapeutic genes in specific tissues in life-threatening diseases." METHODS (ORLANDO), vol. 28, no. 2, October 2002 (2002-10), pages 259-266, XP002304488 ISSN: 1046-2023 the whole document</p>	1,2,5,7, 9-16
Y	<p>HALABY I A ET AL: "Glucocorticoid-regulated VEGF expression in ischemic skeletal muscle" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 5, no. 3, March 2002 (2002-03), pages 300-306, XP002977064 ISSN: 1525-0016 the whole document</p>	1,2,5,7, 9-16,27
Y	<p>ABRUZZESE R V ET AL: "Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system." MOLECULAR THERAPY : THE JOURNAL OF THE AMERICAN SOCIETY OF GENE THERAPY. SEP 2000, vol. 2, no. 3, September 2000 (2000-09), pages 276-287, XP002305133 ISSN: 1525-0016 the whole document</p>	1,2,5,7, 9-16,27

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/026196

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	YAMAGUCHI JUN-ICHI ET AL: "Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization." CIRCULATION, vol. 107, no. 9, 11 March 2003 (2003-03-11), pages 1322-1328, XP002305134 ISSN: 0009-7322 the whole document	17-26,28
Y	----- KOLLET ORIT ET AL: "HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 112, no. 2, July 2003 (2003-07), pages 160-169, XP002289820 ISSN: 0021-9738 the whole document	17-26,28
A	----- GU JIAN ET AL: "Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers" CANCER RESEARCH, vol. 60, no. 19, 1 October 2000 (2000-10-01), pages 5359-5364, XP002305135 ISSN: 0008-5472 abstract	
A	----- QIAO J ET AL: "Tumor-specific transcriptional targeting of suicide gene therapy" GENE THERAPY, vol. 9, no. 3, February 2002 (2002-02), pages 168-175, XP002305136 ISSN: 0969-7128 abstract	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/026196

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 17-26, 28
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)